1. Pink Sheet

Aducanumab's Big Day Arrives, But How Much Will US FDA Panel Vote Matter?

 
• By Brenda Sandburg and Sue Sutter

Agency thinks Biogen’s sucessful Phase III study supports approval, but given the negative outcome of another trial and disease-modifying mechansim of action, an advisory committee endorsement could go a long way in assuring the public the Alzheimer's drug actually works; the panel will comprise 11 voting members, four of whom were added as temporary members for their expertise in neurology, biostatistics and patient advocacy.

Concept of memory loss and brain aging due to dementia and Alzheimer's disease as a medical icon with fall trees shaped as a human head losing leaves
Biogen's Alzheimer's disease drug aducanumab is facing an FDA advisory committee review • Source: Shutterstock

The US Food and Drug Administration’s positive view of Biogen, Inc.’s aducanumab suggests the agency may be primed to approve the Alzheimer’s drug with or without the backing of its external experts.

However, given thediscordant data from two Phase III trials that were prematurely terminated, and the agency's work with Biogen in getting the drug this far down the regulatory path, an endorsement by the Peripheral and Central Nervous System Drugs Advisory Committee could go a long way in bolstering not only the FDA’s credibility

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers